KEAP1 and metabolic dysfunction-associated steatotic liver disease: In addition, the diterpenoid Dehydroabietic Acid activates the Keap1/Nrf2-ARE signalling pathway and attenuates non-alcoholic fatty liver disease (NAFLD).